

info about which IND we're in? Switch

The mandated table of contents section breakout is [here](#)

## Module/granule

**1**
Close full eCTD tree
Add custom appendix

1.1 Form 1574.pdf

1.2 Cover Letter.docx

1.3.1 sponsor contact information.docx

1.3.2 Field copy certification activate granule

1.3.3 Debarment certification activate granule

1.3.4 Financial certification and disclosure activate granule

1.3.5 Patent and exclusivity activate granule

1.12.1.4 Roadmap of Responses from pre-IND meeting.docx

1.12.13 Request for waiver of in vivo studies.docx

1.12.14 Request for categorical exclusion of environmental assessment.docx

1.14.4.2 Investigational drug labeling.docx

1.20 Introduction and General Investigational Plan.docx

LMN-201 Investigator Brochure V2.0.docx

**2**
Open full eCTD tree
Add custom appendix

2.2 Overview.docx

2.3 Quality Overall Summary.docx

2.4 Nonclinical Overview.docx

2.5 Clinical Overview.docx

2.6.1 Introduction.docx

2.6.2 Pharmacology Written Summary.docx

2.6.3 Pharmacology tabulated summary.docx

2.6.4 Pharmacokinetics written summary.docx

2.6.5 Pharmacokinetics tabulated summary.docx

2.6.6 Toxicology written summary.docx

2.6.7 Toxicology tabulated summary.docx

2.7.1 Summary of current studies.docx

**3.2.A**
Open full eCTD tree
Add custom appendix

3.2.A.1 Facilities and equipment (Lumen Bioscience).pdf

3.2.A.2 Adventitious agents safety evaluation (LMN-201, capsules, Lumen).pdf

3.2.A.3 Novel Excipients (LMN-201, Lumen).pdf

**3.2.P**
Open full eCTD tree
Add custom appendix

3.2.P.1 Description and composition (LMN-201, capsules).docx

3.2.P.1 Description and composition of the drug product (placebo, capsules).pdf

3.2.P.2 Pharmaceutical development (placebo, capsules).pdf

3.2.P.2.1 Components of the Drug Product.docx

3.2.P.2.2 Drug product (placebo, capsules).pdf

3.2.P.2.2 Drug Product.docx

3.2.P.2.3 Manufacturing process development (placebo, capsules).pdf

3.2.P.2.3 Manufacturing process development.docx

3.2.P.2.4 Container closure system (placebo, capsules).pdf

3.2.P.2.4 Container closure system.docx

when full tree is open, this button changes color and text to "inactive granule" etc.? and the full tree opens up with "inactive granule" in lighter format (grey text?)

right click:  
– edit granule name  
– other?

3.2.P.2.5 Microbiological attributes (placebo, capsules).pdf  
3.2.P.2.5 Microbiological attributes.docx  
3.2.P.2.6 Compatibility (placebo, capsules).pdf  
3.2.P.2.6 Compatibility.docx  
3.2.P.3.1 Manufacturers (placebo, capsules).pdf  
3.2.P.3.1 Manufacturers.docx  
3.2.P.3.2 Batch formula (placebo, capsules).pdf  
3.2.P.3.2 Batch formula.docx  
3.2.P.3.3 Description of manufacturing process and process controls (placebo, caps  
3.2.P.3.3 Description of manufacturing process and process controls.docx  
3.2.P.3.4 Control of critical steps and intermediates (placebo, capsules).pdf  
3.2.P.3.4 Control of critical steps and intermediates.docx  
3.2.P.3.5 Process validation and or evaluation (placebo, capsules).pdf  
3.2.P.3.5 Process validation and or evaluation.docx  
3.2.P.4 Control of excipients (LMN-201, capsules).docx  
3.2.P.4 Control of excipients (placebo, capsules).pdf  
3.2.P.5.1 Specifications (placebo, capsules).pdf  
3.2.P.5.1 Specifications 29OCT21.docx  
3.2.P.5.1 Specifications.docx  
3.2.P.5.2 Analytical procedures (placebo, capsules).pdf  
3.2.P.5.2 Analytical procedures.docx  
3.2.P.5.3 Validation of analytical procedures (placebo, capsules).pdf  
3.2.P.5.3 Validation of analytical procedures.docx  
3.2.P.5.4 Batch analyses (placebo, capsules)\_26OCT21.docx  
3.2.P.5.4 Batch analyses (placebo, capsules).pdf  
3.2.P.5.4 Batch analyses.docx  
3.2.P.5.5 Characterization of impurities (placebo, capsules).pdf  
3.2.P.5.5 Characterization of impurities.docx  
3.2.P.5.6 Justification of specifications 29OCT21.docx  
3.2.P.5.6 Justification of specifications.docx  
3.2.P.6 Reference Standard.docx  
3.2.P.6 Reference standards or materials (placebo, capsules).pdf  
3.2.P.7 Container closure system (LMN-201, capsules).pdf  
3.2.P.7 Container closure system (placebo, capsules).pdf  
3.2.P.8.1 Stability summary and conclusion (placebo, capsules).pdf  
3.2.P.8.1 Stability summary and conclusion.docx  
3.2.P.8.3 Stability data (LMN-201, capsules).docx  
3.2.P.8.3 Stability data (placebo, capsules).pdf

**3.2.S** [Open full eCTD tree](#) [Add custom appendix](#)

3.2.S.1 General Information (SP1308 SP1312 SP1313 SP1287, Lumen Bioscience)  
3.2.S.2.1 Manufacturer.docx  
3.2.S.2.2 Description of manufacturing process and process controls.docx  
3.2.S.2.3 Control of materials (SP1308 SP1312 SP1313 SP1287, Lumen Bioscience  
3.2.S.2.4 Control of critical steps and intermediates.docx  
3.2.S.2.5 Process validation and or evaluation.docx  
3.2.S.3.1 Elucidation of structure and other characteristics.docx

3.2.S.3.2 Impurities.docx  
3.2.S.4.1 Specification.docx  
3.2.S.4.2 Analytical procedures.docx  
3.2.S.4.4 Batch analyses.docx  
3.2.S.4.5 Justification of specification.docx  
3.2.S.5 Reference standards or materials (SP1308 SP1312 SP1313 SP1287, Lumen Bioscience).docx  
3.2.S.6 Container closure system (SP1308 SP1312 SP1313 SP1287, Lumen Bioscience).docx  
3.2.S.7.1 Stability summary and conclusions.docx  
3.2.S.7.3 Stability data (SP1308 SP1312 SP1313 SP1287, Lumen Bioscience).docx  
Appendix 3.2.S.4.2 AM-001 Lysin Turbidity Reduction Assay Rev. 001.pdf  
Appendix 3.2.S.4.2 AM-002 Enzyme Linked Immunosorbent Assay Rev. 001.pdf  
Appendix 3.2.S.4.2 AM-003 Jess Simple Western Assay Rev.1.pdf  
Appendix 3.2.S.4.2 AM-004 BCA Protein Concentration Determination Rev.1.pdf  
Appendix 3.2.S.4.4 LMN-201 Product Information\_CofA.pdf

e									
SN0013	SN0012	SN0011	SN0010	SN0009	SN0008	SN0007	SN0006	SN0005	SN0004

Button here to apply the XML rules and hyperlink the cross references as required by ICH4, then lock all as

text to "close granules showing"	Uploaded	Uploaded	Uploaded	Uploaded	Uploaded	Uploaded	Uploaded	Uploaded	Uploaded
		Uploaded	Uploaded	Uploaded	Uploaded	Uploaded	Uploaded	Uploaded	Uploaded

draft	Uploaded	Uploaded	Uploaded	Uploaded	Uploaded	Uploaded	Uploaded	Uploaded	Uploaded
-------	----------	----------	----------	----------	----------	----------	----------	----------	----------

Clicking this button: gathers the latest versions of all subsections in that module, locks them in Sharef (locked), and compiles them into one Word file with section page breaks as per ICH eCTD guidance. Th "locked for compiled editing" in each granule and this button switches to show "re-atomize" and whe accepted in the compiled module word doc and the granules are overwritten with re-atomized docs.

final							Uploaded		Uploaded
Open compiled redline									

	Uploaded	Uploaded
	Uploaded	Uploaded
	Uploaded	Uploaded
	Uploaded	Uploaded
final	Uploaded	Uploaded
	Uploaded	Uploaded
	Uploaded	Uploaded
	Uploaded	Uploaded
	Uploaded	Uploaded


draft	hover: last edit date file location
-------	---

right click:  
 – edit  
 – open doc as redline against most recent version of this granule  
 – upload replacement Word doc  
 – download Word doc  
 – open folder in SharePoint  
 – change drafting status (draft/final/uploaded)

Uploaded	Uploaded	Uploaded
----------	----------	----------

Uploaded

	Uploaded	
final	Uploaded	
	Uploaded	
	Uploaded	
	Uploaded	
		Uploaded
		Uploaded



final	Uploaded
final	Uploaded
final	Uploaded
final	Uploaded


Uploaded	Uploaded
Uploaded	

n Bioscience).docx	
ence).docx	Uploaded
final	Uploaded
final	Uploaded

new

new







Uploaded	Uploaded	X
Uploaded	Uploaded	X
Uploaded	Uploaded	X
Uploaded	Uploaded	X
Uploaded	Uploaded	X
	Uploaded	X
	Uploaded	X
Uploaded	Uploaded	X
Uploaded		X
		n/a
new		n/a
		n/a
		n/a
new		n/a

controls,  
m

**Table 1.** Module 2 (paper and eCTD v3.2.2 submissions)

Module 2	2.1	The TOC is only called for in the paper version of the CTD; there is no entry needed for the eCTD	
	2.2		
	2.3	Introduction	
	Note 1	2.3.S Note 2	2.3.S.1
			2.3.S.2
			2.3.S.3
			2.3.S.4
			2.3.S.5
			2.3.S.6
			2.3.S.7
		2.3.P Note 3	2.3.P.1
			2.3.P.2
			2.3.P.3
			2.3.P.4
			2.3.P.5
			2.3.P.6
			2.3.P.7
			2.3.P.8
		2.3.A	2.3.A.1
			2.3.A.2
			2.3.A.3
		2.3.R	
	2.4		
	2.5		
	2.6	2.6.1	
		2.6.2	
		2.6.3	
		2.6.4	
		2.6.5	
		2.6.6	
		2.6.7	
	2.7	2.7.1	
		2.7.2	
		2.7.3	
		Note 4	
		2.7.4	
		2.7.5	
		2.7.6	

ICH guideline M4 (R4) on common technical document (CTD) for the registration of pharmaceuticals for human use - organisation of CTD  
EMA/CPMP/ICH/2887/1999

#### Feature creep:

- regulatory comments tracker?
  - somehow tag to different underlying granules?
  - track responses over time
  - separately library to track underlying documents
- how about a tracker for assay qualification and validation?
- Multi-jurisdiction tracking
  - different module 1 by country
  - how to track currency of lower modules — GUIDs?
  - possibility to redline consolidated modules against its counterpart currently in eCTD by country?
- AI library of prior INDs and prior FDA comments and published guidance from ICH
- push a button to get AI compliance report?
- table formatting ribbon custom tools in MSFT Word





effect in another

and FDA etc.

